Clinical Trials Browser

Phase 1/2 × Neoplasms × Tumor-Agnostic × Clear all

NCT07630974 2026-06-05

MK-9999-01D

Phase 1/2 Not yet recruiting

Neoplasms

NCT04145622 2026-05-29

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT05674825 2026-05-22

MCW I-PREDICT

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

Neoplasms

NCT02130492 2026-05-15

A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

Phase 1/2 Suspended

Neoplasms

NCT06941272 2026-05-12

MK-9999-01C

Phase 1/2 Recruiting

Neoplasms

NCT02908906 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Phase 1/2 Active not recruiting

Neoplasms

NCT06818643 2026-05-08

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Phase 1/2 Recruiting

Neoplasms

NCT05394337 2026-05-05

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1/2 Recruiting

Neoplasms

NCT03872778 2026-04-30

NeoRay

Phase 1/2 Completed

Neoplasms

NCT03535246 2026-04-24

Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells

Phase 1/2 Recruiting

Neoplasms

NCT03614650 2026-04-24

Immunotherapy Treating GI Cancer

Phase 1/2 Recruiting

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Phase 1/2 Active not recruiting

Neoplasms

NCT05975073 2026-04-22

A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT05120596 2026-04-13

First in Human Study of T3P-Y058-739 (T3P)

Phase 1/2 Recruiting

Neoplasms

NCT06238687 2026-04-06

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Phase 1/2 Completed

Neoplasms

NCT07510828 2026-04-06

PRISM-NK

Phase 1/2 Recruiting

Neoplasms

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

Neoplasms

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT07498725 2026-03-27

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors

Phase 1/2 Not yet recruiting

Neoplasms

NCT05046171 2026-03-24

Decreasing Polypharmacy in Older Adults With Curable Cancers Trial

Phase 1/2 Completed

Neoplasms

NCT04333706 2026-03-10

EMPOWER

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT04723810 2026-03-09

TumorGlow Intraoperative Molecular Imaging (IMI)

Phase 1/2 Recruiting

Neoplasms

NCT07354100 2026-03-04

(BLOOM)

Phase 1/2 Not yet recruiting

Neoplasms

NCT06014658 2026-03-02

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT06056791 2026-02-27

CaRe

Phase 1/2 Completed

Neoplasms

NCT06211933 2026-02-12

PULS

Phase 1/2 Suspended

Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Phase 1/2 Active not recruiting

Neoplasms

NCT06634849 2026-02-10

An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Phase 1/2 Recruiting

Neoplasms

NCT03260023 2026-02-05

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Phase 1/2 Active not recruiting

143 enrolled 24 charts

Neoplasms

NCT04260529 2026-01-29

CICILIA

Phase 1/2 Completed

60 enrolled 18 charts

Neoplasms

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Phase 1/2 Recruiting

Neoplasms

NCT07112222 2026-01-26

A Study of LM-350 in Subjects With Advanced Solid Tumours

Phase 1/2 Recruiting

Neoplasms

NCT07073534 2026-01-22

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

Phase 1/2 Recruiting

Neoplasms

NCT03096093 2026-01-20

Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer

Phase 1/2 Active not recruiting

Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT05741242 2026-01-15

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Phase 1/2 Enrolling by invitation

Neoplasms

NCT05450562 2026-01-14

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms

NCT07197827 2025-12-24

A Study of YL242 in Subjects With Advanced Solid Tumors

Phase 1/2 Recruiting

Neoplasms

NCT04009681 2025-12-15

HAMMER

Phase 1/2 Terminated

Neoplasm Metastasis, Neoplasms

NCT05383170 2025-11-28

Catalyst

Phase 1/2 Completed

6 enrolled 11 charts

Neoplasms

NCT06311851 2025-11-25

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT06184035 2025-11-20

Tumorad

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

NCT03363893 2025-11-12

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Phase 1/2 Completed

Neoplasms

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT05697406 2025-09-22

HC-MRI

Phase 1/2 Recruiting

Neoplasms

NCT06193902 2025-09-03

AERIAL

Phase 1/2 Recruiting

Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

Neoplasms